A practical reference on Peptide stability: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-01-30. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide, 28 residues | N-terminal fragment of prothymosin alpha |
| Molecular mass | About 3108 Da | Acetylated form |
| Isoelectric point | Near 4.2 | Acidic peptide |
| Appearance | White to off-white lyophilized powder | Common supplied form |
| Typical storage | -20 °C or below, dry | Solution stability is lower |
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Identity and purity testing for thymosin alpha 1 relies mainly on reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatography separates the parent peptide from truncated or modified variants, while mass spectrometry confirms the expected molecular mass. Amino acid analysis and peptide mapping provide additional sequence confirmation. Counterion content, water content, and residual solvents are measured separately as part of specification testing. No single method captures every attribute, so laboratories combine several techniques.
The peptide lacks cysteine, methionine, and tryptophan, so disulfide scrambling and sulfur oxidation are not major degradation routes. Instead, aspartate residues can undergo isomerization or cyclization to succinimide intermediates, generating isoaspartate variants. Hydrolysis of peptide bonds also occurs slowly in solution. These changes may reduce biological activity even when the main peak remains detectable. Stability studies therefore track both potency and the appearance of related substances.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
==== Thailand ==== In Thailand, Mister Donut has been a leader in the Thai donut market since 1978 and uses the slogan "Donut for Fun". As of December 2011, Thailand was the "largest market outside Japan for Mister Donut in terms of sales volume." Mister Donut has more than 320 branches across Thailand with more opening yearly. They include stand-alone stores as well as branches at shopping malls and supermarkets. In 2014, donut consumption increased 10 and 15 per cent in Thailand, with Mister Donut accounting for half of that increase. In 2015, Thailand's Central Restaurants Group announced plans to open 30 new outlets in 2015, bringing its store number to 350. The company stated that it would be able to sell "its doughnuts in all 77 provinces by year end." Central has also stated it is considering expanding Mister Donut in Malaysia, the Philippines, and Indonesia.
== As a defensive adaptation == The slime coat of reef fish contains mycosporine-like amino acids (MAAs) which protect the fish from sun damage by absorbing radiation. The greatest number of MAAs is found on the dorsal side of the fish, which is exposed to more radiation. Animals cannot synthesize MAAs, requiring fish to sequester them from their diet. Under water, fish are exposed to a greater number of microorganisms than animals whose skin is exposed mainly to air. In the absence of a stratum corneum, the slime coat serves to protect the fish from attack from harmful microorganisms. This is chiefly done by sloughing off microbes which become trapped in the slime coat, but the slime coat contains antimicrobial peptides and other defensive properties such as lysozyme and C-reactive protein. Parrotfish create extra mucus during sleep which covers their bodies in a cocoon-like structure. It protects them from predators and parasites by masking their scent and providing a physical barrier against them.
In 1869 Dmitrii Mendeleev reported that when he arranged the elements in a row according to their atomic weights, there was a certain periodicity to them. For instance, the second element, lithium, had similar properties to the ninth element, sodium, and the sixteenth element, potassium — a period of seven. Likewise, beryllium, magnesium, and calcium were similar and all were seven places apart from each other on Mendeleev's table. Using these patterns, Mendeleev predicted the existence and properties of new elements, which were later discovered in nature: scandium, gallium, and germanium. Moreover, the periodic table could predict how many atoms of other elements that an atom could bond with — e.g., germanium and carbon are in the same group on the table and their atoms both combine with two oxygen atoms each (GeO2 and CO2). Mendeleev found these patterns validated atomic theory because it showed that the elements could be categorized by their atomic weight. Inserting a new element into the middle of a period would break the parallel between that period and the next, and would also violate Dalton's law of multiple proportions.
Sources: en.wikipedia.org
=== Electrical properties === Most conventional polymers such as polyethylene are electrical insulators, but the development of polymers containing π-conjugated bonds has led to a wealth of polymer-based semiconductors, such as polythiophenes. This has led to many applications in the field of organic electronics.
== Exhibition == Lindow Man is held in the collection of the British Museum in London, where his remains were first publicly displayed in July 1986 as part of the exhibition Archaeology in Britain. In 1997, they were moved to the museum's Iron Age gallery. His remains have also been loaned to other museums for temporary exhibitions. Manchester Museum displayed him in 1987, 1991 and from 19 April 2008 to 19 April 2009. The 2008–2009 exhibition, Lindow Man: A Bog Body Mystery, won the award for Best Archaeological Innovation at the 2010 British Archaeological Awards. His remains were subsequently exhibited at the Great North Museum in Newcastle upon Tyne from August to November 2009, before returning to the British Museum.
== Early life and education == Robert Finnigan was born on May 27, 1927, in Buffalo, New York, to Charles M. and Marie F. Finnigan. He was one of seven children, who were raised primarily by their father after their mother's early death. Finnigan entered the United States Naval Academy in Annapolis, Maryland, in June 1945, graduating in 1949 with a Bachelor of Science. On April 1, 1950, he married Bette Earl Van Horn at Perrin Air Force Base in Sherman, Texas. The couple had met while he was at Tyndall Air Force Base near Panama City, Florida. Because of his strong interest and aptitude in electrical engineering, he was able to enroll in an Air Force Institute of Technology program that sent qualified officers to graduate school. In 1952, he entered the University of Illinois at Urbana–Champaign, receiving an M.S. in electrical engineering in 1954 and a Ph.D. in electrical engineering in 1957. His master's thesis work with Edward C. Jordan used the ILLIAC to solve complex mathematical functions in antenna theory. For his Ph.D. he researched servomechanism theory with Gilbert Fett, completing the thesis Transient Analysis of Non-Linear Servomechanisms Using Describing Functions with Root-Locus Techniques.
Sources: en.wikipedia.org
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.
It is usually classified as an immunomodulatory peptide rather than a classical hormone. It derives from the larger protein prothymosin alpha and acts mainly on immune cells. The thymosin label covers a group of distinct peptides, so the naming can be misleading.